| The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy N Albadari, S Deng, W Li Expert opinion on drug discovery 14 (7), 667-682, 2019 | 256 | 2019 |
| Structure–activity relationship study of novel 6-aryl-2-benzoyl-pyridines as tubulin polymerization inhibitors with potent antiproliferative properties H Chen, S Deng, Y Wang, N Albadari, G Kumar, D Ma, W Li, SW White, ... Journal of Medicinal Chemistry 63 (2), 827-846, 2019 | 39 | 2019 |
| Design, synthesis, and biological evaluation of stable colchicine-binding site tubulin inhibitors 6-aryl-2-benzoyl-pyridines as potential anticancer agents H Chen, S Deng, N Albadari, MK Yun, S Zhang, Y Li, D Ma, DN Parke, ... Journal of medicinal chemistry 64 (16), 12049-12074, 2021 | 34 | 2021 |
| Survivin small molecules inhibitors: recent advances and challenges N Albadari, W Li Molecules 28 (3), 1376, 2023 | 22 | 2023 |
| Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold N Albadari, S Deng, H Chen, G Zhao, J Yue, S Zhang, DD Miller, Z Wu, ... European journal of medicinal chemistry 224, 113719, 2021 | 5 | 2021 |
| Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling N Albadari, Y Xie, W Li Frontiers in Pharmacology 14, 1340401, 2024 | 2 | 2024 |
| ABCB1-Dependent Collateral Sensitivity of Multidrug-Resistant Colorectal Cancer Cells to the Survivin Inhibitor MX106-4C ZN Lei, N Albadari, QX Teng, H Rahman, JQ Wang, Z Wu, D Ma, ... Drug Resistance Updates, 101065, 2024 | 1 | 2024 |
| MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma T Liu, L Gu, Z Wu, N Albadari, W Li, M Zhou Frontiers in Oncology 12, 1058726, 2022 | 1 | 2022 |
| MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future W Wang, N Albadari, Y Du, JF Fowler, HT Sang, W Xian, F McKeon, W Li, ... Pharmacological Reviews 76 (3), 414-453, 2024 | | 2024 |
| Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable? W Wang, Y Du, S Datta, JF Fowler, HT Sang, NG Albadari, W Li, J Foster, ... Genes & Diseases, 101156, 2023 | | 2023 |
| Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold N Albadari, Y Xie, T Liu, R Wang, L Gu, M Zhou, Z Wu, W Li European Journal of Medicinal Chemistry 255, 115423, 2023 | | 2023 |
| Colchicine binding site agents as potent tubulin inhibitors suppressing triple negative breast cancer S Deng, H Chen, R Krutilina, NG Albadari, TN Seagroves, DD Miller, W Li Cancer Research 79 (13_Supplement), 4608-4608, 2019 | | 2019 |
| Discovery of novel 6-aryl-2-benzoyl-pyridines as tubulin polymerization inhibitor with potent antiproliferative properties H Chen, S Deng, N Albadari, D Miller, W Li ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 257, 2019 | | 2019 |
| An Mdm2 Degrader Shows Potent Cytotoxicity to Mdm2-Overexpressing Acute Lymphoblastic Leukemia Cells with Minimal Toxicity to Normal Cells/Tissues T Liu, L Gu, A Mui, Z Wu, N Albadari, M Zhou, W Li Tissues, 0 | | |
